Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for its Epigenetic Reprogramming Therapies

Turn Biotechnologies, Inc. California

ARMMs brings precision medicine through targeted, non-viral vesicular deliverySynergy of ARMMs and eTurna™ LNP platforms means company can deliver broad range of larger, more varied cargoes – including gene editors, proteins and RNA-based therapiesTwo delivery technologies make possible the safe, scalable and precise epigenetic reprogramming for candidates across ophthalmic, dermatologic and immune therapiesPreclinical data for ARMMs technology shows effective delivery in a variety of tissues, including retinal, lung, nervous system, liver and spleen.or [phone]

Logo - https://mma.prnewswire.com/media/1935529/5234788/TURN_LOGO_HI_RES_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/turn-biotechnologies-acquires-armms-vesicular-technology-to-increase-access-to-tissue-targets-for-its-epigenetic-reprogramming-therapies-302411780.html